Plain-English translation of NCT07405229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
If you've survived a cardiac arrest with no clear medical explanation, your heart is at risk of stopping again. This trial is testing whether beta-blockers—a common, affordable heart medication—can reduce dangerous heart rhythms and prevent another cardiac arrest. Researchers will also study whether genetic testing and heart rhythm patterns can help predict who is most at risk.
Right now, doctors recommend an implantable defibrillator (a device that shocks the heart if needed) for people like you, but there's no standard medication approach to prevent recurrence. This study will find out whether this medication actually helps reduce dangerous heart rhythms and whether we can better predict who needs it most.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take beta-blocker medication or receive standard care without it. Throughout the study, you'll have heart monitoring, blood tests, and genetic testing to see if the medication reduces dangerous heart rhythms. Researchers will also ask about your quality of life and any symptoms you experience. The study involves visits to the hospital and follow-up assessments over time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Denmark
Phase
Post-approval monitoring
Sponsor
Bo Gregers Winkel
Collaborators
Novo Nordisk Foundation, Per Henriksen Foundation
Enrollment target
~218 participants
Started
May 2018
Primary completion
December 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bo G Winkel, MD, PhD
The Heart Center, Rigshospitalet
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.